Genprex Inc (GNPX)
3.14
+0.72
(+29.75%)
USD |
NASDAQ |
May 31, 16:00
3.54
+0.40
(+12.74%)
After-Hours: 20:00
Genprex SG&A Expense (Quarterly): 2.720M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.720M |
December 31, 2023 | 2.270M |
September 30, 2023 | 3.166M |
June 30, 2023 | 4.055M |
March 31, 2023 | 3.950M |
December 31, 2022 | 3.188M |
September 30, 2022 | 3.006M |
June 30, 2022 | 2.837M |
March 31, 2022 | 3.264M |
December 31, 2021 | 2.902M |
September 30, 2021 | 2.000M |
June 30, 2021 | 2.458M |
March 31, 2021 | 4.316M |
December 31, 2020 | 2.904M |
September 30, 2020 | 1.422M |
June 30, 2020 | 2.217M |
March 31, 2020 | 4.093M |
Date | Value |
---|---|
December 31, 2019 | 1.934M |
September 30, 2019 | 1.91M |
June 30, 2019 | 3.199M |
March 31, 2019 | 1.660M |
December 31, 2018 | 3.124M |
September 30, 2018 | 1.706M |
June 30, 2018 | 5.922M |
March 31, 2018 | 0.6341M |
December 31, 2017 | 0.6026M |
September 30, 2017 | 0.6588M |
June 30, 2017 | 1.075M |
March 31, 2017 | 0.6823M |
December 31, 2016 | 0.8695M |
September 30, 2016 | 0.6297M |
June 30, 2016 | 2.010M |
March 31, 2016 | 0.2674M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.422M
Minimum
Sep 2020
4.316M
Maximum
Mar 2021
2.891M
Average
2.903M
Median
SG&A Expense (Quarterly) Benchmarks
Lifecore Biomedical Inc | 11.69M |
Jaguar Health Inc | 5.824M |
Aquestive Therapeutics Inc | 10.69M |
TFF Pharmaceuticals Inc | 2.320M |
Calidi Biotherapeutics Inc | 4.009M |